To elucidate the potential effect of CD8 checkpoint blockade in therapeutic angiogenesis in T2D, we blocked the activation, proliferation and/or infiltration of CD8+ T-cells with a non-lytic anti-CD8 mAb (clone YTS105) as previously described 11, 12 (Figure 3A). The gene discussed is CD8A; the disease is type 2 diabetes mellitus.